Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 5, 2006, Pages 563-572

  Bruce, R Douglas ^a   Altice, Frederick L ^a   Gourevitch, Marc N ^b   Friedland, Gerald H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Buprenorphine; Drug interactions; HIV AIDS; Methadone; Pharmacokinetics

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; BUPRENORPHINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; OPIATE AGONIST; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; AIDS PATIENT; BRADYCARDIA; CLINICAL PRACTICE; CLINICAL TRIAL; COMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DRUG DEPENDENCE; FLUSHING; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHERMIA; IRRITABILITY; LETHARGY; MIOSIS; MUSCLE SPASM; MYDRIASIS; NAUSEA; OPIATE ADDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; RHINORRHEA; SIDE EFFECT; STUPOR; TACHYCARDIA; TREMOR; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANALGESICS, OPIOID; ANTI-HIV AGENTS; BUPRENORPHINE; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; METHADONE;

EID: 33646776797     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000219769.89679.ec     Document Type: Review

References (90)

1. Dolan K, Hall W, Wodak A. Methadone maintenance reduces injecting in prison. Br Med J. 1996;312:1162.
2. Donny EC, Walsh SL, Bigelow GE, et al. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology. 2000;161:202-212.
3. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002;347:817-823.
4. San-Andres FJ, Rubio R, Castilla J, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis. 2003;36:1177-1185.
5. van Sighem AI, van de Wiel MA, Ghani AC, et al. ATHENA Cohort Study Group. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS. 2003;17:2227-2236.
6. Mocroft A, Ledergerber B, Katlama C, et al. EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
7. Tramarin A, Campostrini S, Postma MJ, et al. The Palladio Study Group. A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy. Pharmacoeconomics. 2004;22:43-53.
8. Anis AH, Guh D, Hogg RS, et al. The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Pharmacoeconomics. 2000;18:393-404.
9. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: position paper. World Health Organization, United Nations Office on Drugs and Crime, UNAIDS; 2004:1-36.
10. Schobelock MJ. Product Discontinuation Notice. ORLAAM® (Levomethadyl hydrochloride acetate) Oral Solution, 10 mg/mL, CII. NDC 0054-3649-63; August 2003.
11. Kinlock TW, Battjes RJ, Schwartz RP. A novel opioid maintenance program for prisoners: preliminary findings. J Subst Abuse Treat. 2002;22(3):141-147.
12. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest. 2003;33(suppl 2):6-9.
13. Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther. 1972;13:923-930.
14. Meresaar U, Nilsson MI, Holmstrand J, et al. Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur J Clin Pharmacol. 1981;20:473-478.
15. Nilsson MI, Meresaar U, Anggard E. Clinical pharmacokinetics of methadone. Acta Anaesthesiol Scand. 1982;74:66-69.
16. Verebely K, Mule S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther. 1975;18:180-190.
17. Novick DM, Kreek MJ, Arns PA, et al. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. Alcohol Clin Exp Res. 1985;9(4):349-354.
18. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003;31:742-747.
19. Begre S, von Bardeleben U, Ladewig D, et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol. 2002;22:211-215.
20. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996;9:365-373.
21. Wu D, Otton SV, Sproule BA, et al. Inhibition of cytochrome P450 2D6 (CYP2 D6) by methadone. Br J Clin Pharmacol. 1993;35:30-34.
22. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004;16:36-44.
23. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorephic human cytochrome P450 enzymes: an opportunity for individual drug treatment. Trends Pharmacol Sci. 1999;20:342-349.
24. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41:1153-1193.
25. Iribarne C, Picart D, Dreano Y, et al. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997;60:1953-1964.
26. Kobayashi K, Yamamoto T, Chiba K, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P4503A4. Drug Metab Dispos. 1998;26:818-821.
27. Umehara K, Shimokawa Y, Miyamoto G. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull. 2002;25:682-685.
28. Zhang W, Ramamoorthy Y, Tyndale RF, et al. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003;31(6):768-772.
29. Sommadossi JP. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. AIDS. 1998;12(suppl 3):S1-S8.
30. Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther. 1998;20:2-25.
31. Sankatsing SUC, Beijnen JH, Schinkel AH, et al. P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother. 2004;48:1073-1081.
32. Veal GJ, Back DJ. Metabolism of zidovudine. Gen Pharmacol. 1995;26:1469-1475.
33. Decks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-R-(phosphonomethoxy)propyl] adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother. 1998;42:2380-2384.
34. Katzung B. Basic & Clinical Pharmacology. McGraw-Hill; 2004[electronic publishing].
35. Heald AE, Hussey EK, Hall ST, et al. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40:1514-1518.
36. Riska P, Erickson D, Joseph D, et al. Nevirapine, a nonnucleoside reverse transcriptase inhibitor: metabolism in man, mouse, rat, dog, cynomolgus monkey and chimpanzee. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Tu.B.2326.
37. Sustiva Product Information. Wilmington, DE: DuPont Pharmaceuticals; 1998.
38. Kappelhoff BS, Crommentuyn KM, de Maat MM, et al. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet. 2004;43:845-853.
39. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281-1292.
40. Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci. 1998;87:803-807.
41. Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquir Immune Defic Syndr. 2003;34(suppl 1):S91-S94.
42. Hansten PD. Drug interactions. In: Koda-Kimble MA ed. Applied Therapeutics the Clinical Use of Drugs. Vancouver: Applied Therapeutics Inc., 1995: 1-3.
43. Faragon JJ, Piliero PJ. Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Reader. 2003;13:433-434.
44. Schwartz EL, Brechbühl AB, Kahl P, et al. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infections. J Acquir Immune Defic Syndr. 1992;5:619-626.
45. McCance-Katz EF, Rainey PM, Jatlow P, et al. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr. 1998;18:435-443.
46. McCance-Katz EF, Rainey PM, Friedland GH, et al. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict. 2001;10:296-307.
47. Rainey PM, Friedland GH, Snidow JW, et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects (NZTA4003). Am J Addict. 2002;11:66-74.
48. Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr. 24(3):241-248.
49. Friedland G, Rainey P, Jatlow P, et al. Pharmacokinetics (pK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy. 14th International AIDS Conference; July 7-12, 2002; Barcelona, Spain.
50. Staszewski S, Haberl A, Gute P, et al. Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users. Antivir Ther. 1998;3(suppl 4):55-56.
51. Lucas GM, Weidle PJ, Hader S, et al. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis. 2004;38(suppl 5):S4049.
52. Sellers E, Lam R, McDowell J, et al. The pharmacokinetics (PK) of abacavir (ABC) and methadone (M) following co-administration: CNAA1012. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, CA. Abstract 305.
53. Smith P, Kearney B, Cloen D, et al. Tenofovir DF does not affect the pharmacokinetics or pharmacodynamics of methadone. 2nd IAS Conference on HIV Pathogenesis and Treatment; July 2003; Paris, France. Abstract 869.
54. Altice FL, Friedland GH, Cooney EL. Nevirapine-induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13:957-962.
55. Otero MJ, Fuertes A, Sanchez R, et al. Nevaripine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS. 1999;13(8):1004-1005.
56. Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy. 1999;19:471-472.
57. Pinzanni V, Faucherre V, Peyiere H, et al. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother. 2000;34:405-407.
58. Clarke SM, Mulcahy F, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis. 2001;33:1595-1597.
59. Clarke SM, Mulcahy FM. Efavirenz therapy in drug users. HIV Med. 2000;1(suppl 1):15-17.
60. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001;51:213-217.
61. Marzolini C, Troillet N, Telenti A, et al. Efavirenz decreases methadone blood concentrations. AIDS. 2000;14:1291.
62. Tashima K, Bose T, Gormley J, et al. The potential impact of efavirenz on methadone maintenance. Ninth European Congress of Clinical Microbiology and Infectious Diseases; March 21-24, 1999; Berlin, Germany. Abstract P0552.
63. McCance-Katz, EF. Antiretroviral therapy in injection drug users with HIV disease: using drug interactions to design more effective treatment. Paper presented at: Interactions Between Drugs of Abuse and Pharmacotherapeutics Used in the Treatment of Infections, Drug Abuse, and Mental Disorders; April 13, 2002; Washington, DC.
64. Booker B, Smith P, Forrest A, et al. Lack of effect of methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) & N-delavirdine (abstract A 490). Paper presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago; December 16-19, 2001:14.
65. Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylation by three HIV-1 protease inhibitors. Drug Metab Dispos. 1998;26:257-260.
66. Hsu A, Granneman GR, Carothers L, et al. Ritonavir does not increase methadone exposure in healthy volunteers. Fifth Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, IL. Abstract 324.
67. McCance-Katz EF, Rainey PM, Friedland G, et al. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis. 2003;37:476-482.
68. Cantilena L, McCrea J, Blazes D, et al. Lack of pharmacokinetic interaction between indinavir and methadone (abstract PI-74). Clin Pharmacol Ther. 1999;65:135.
69. Gerber JG, Rosenkranz S, Segal Y, et al. ACTG 401 Study Team. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr. 2001;27:153-160.
70. Shelton MJ, Cloen D, DiFrancesco R, et al. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J Clin Pharmacol. 2004;44:293-304.
71. Hsyu PH, Lillibridge JH, Maroldo L, et al. Pharmacokinetic(PK) and pharmacodynamic (PD) interactions between nelfinavir and methadone. Seventh Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract 87.
72. McCance-Katz EF, Rainey PM, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am J Addict. 2004;13:163-180.
73. Smith PF, Booker BM, Difrancesco R, et al. Effect of methadone or LAAM on the pharmacokinetics of nelfinavir and M8. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy 2001. Abstract 491.
74. Baede-van Dijk PA, Hugen PWH, Verweij-van Wissen C, et al. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS. 2001;15:991-998.
75. McCance-Katz EF, Farber S, Selwyn PO, et al. Decrease in methadone levels with nelfinavir mesylate. Am J Psychiatry. 2000;157(3):481.
76. Maroldo L, Manocchio S, Artenstein A, et al. Lack of effect on nelfinavir mesylate on maintenance methadone dose requirement. XIII International AIDS Conference; 2000. Abstract WePeB4120.
77. Brown LS, Chu M, Aug C, et al. The use of nelfinavir and 2 nuclesoide concomitantly with methadone is effective and well-tolerated in hepatitis C co-infected patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001. Abstract 206.
78. Hendrix CW, Wakeford J, Wire MR, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after co-administration with amprenavir in opioid-dependent subjects. Pharmacotherapy. 2004;24(9):1110-1121.
79. Product information: Agenerase(R), amprenavir. GlaxoSmithKline, Reasearch Triangle Park, NC (PI revised August 2002); revised September 2002.
80. Bart PA, Rizzzardi PG, Gallant S, et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit. 2001;23:553-555.
81. Clarke S, Mulcahy F, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis. 2002;34:1143-1145.
82. Stevens RC, Rapaport S, Maroldo-Connelly L, et al. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2003;33:650-651.
83. Bertz R, Hsu A, Lam W, et al. Pharmacokinetic interactions between lopinavir/ritonavir (ABT-378/r) and other non-HIV drugs. AIDS. 2000;14(suppl 4):S100.
84. Product information: Kaletra(R), lopinavir/ritonavir. Abbott Laboratories, Chicago, IL.
85. Friedland GH, Andrews L, Schreibman T, et al. Lack of an effect of Atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS. October 2005;19(15):1635-1641.
86. Product information: Aptivus(R), tipranavir. Boehringer Ingelheim, Ridgefield, CT.
87. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939; 2004; Rockville, MD: Substance Abuse and Mental Health Services Administration.
88. McCance-Katz E, Pade P, Friedland G, et al. Efavirenz decreases buprenorphine exposure, but is not associated with opiate withdrawal in opioid dependent individuals. 12th Conference on Retroviruses and Opportunistic Infections; 2005; Abstract 653.
89. McCance-Katz EF, Rainey PM, Friedland G, et al. Morse GD, Moody DE, Jatlow P. Clinical Buprenorphine versus Methadone in Opioid Dependent Individuals Receiving HIV Pharmacotheraphy, American Association for the Treatment of Opioid Dependence, Atlanta, GA, April 2006.
90. Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS. March 2006;20(5):783-784.